Anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with lung cancer

EORTC PEARLS

Coordinating investigator

Dr. med.
Alessandra
Curioni Fontecedro
UniversitätsSpital Zürich - Klinik und Poliklinik für Onkologie
+41 44 255 89 02

For further information on the EORTC PEARLS trial, please consult the EORTC website

All trials